Key Takeaways ESPR posted a Q3 loss of $0.16 per share, which missed estimates and widened from last year's$0.15 loss.Q3 revenues surged 69% year over year to $87.3 million, driven by higher collaboration royalties and sales.ESPR expects 2025 operating expenses of$215-$235 million and aims for profitability in early 2026.Esperion Therapeutics (ESPR) incurred a loss of 16 cents per share in the third quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 9 cents. The company had in ...